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Introduction
Patients with type 2 diabetes characteristically experi-
ence a gradual decline in glycaemic control and pro-
gression from oral glucose-lowering monotherapy to
combination therapy and ultimately to exogenous
insulin therapy (1,2). A decrease in the number of
functional insulin-producing b-cells contributes to
the pathological decline in glycaemic control typically
seen in type 2 diabetes (3) and preserving b-cell
function has emerged as a vital component of long-
term management strategies.
Already at diagnosis of type 2 diabetes about 50%
of insulin secretion capacity is lost (4). There is now
increasing evidence available that near to normal glu-
cose control prevents progressive deterioration of
insulin secretion. Therefore, a move towards introdu-
cing combination therapy earlier in the course of
type 2 diabetes with the aim of preserving glycaemic
control and b-cell function and thereby improving
long-term outcomes is considered as a better
approach to meet the dual defect in pathophysiology
of type 2 diabetes. Such an approach poses the chal-
lenge of deﬁning optimal combination regimens and
the point at which to introduce them. Recent studies
suggest that early, aggressive dual or even triple com-
bination therapy in newly diagnosed patients slows
the decline in glycaemic control compared with
standard monotherapies (5,6). Intervening before the
onset of frank type 2 diabetes in high-risk groups,
such as those with gestational onset diabetes (7,8) or
individuals with impaired glucose tolerance (9,10), is
also emerging as a relevant approach to reducing the
long-term morbidity and mortality of this chronic
disease.
Insulin resistance is a core feature of type 2 diabe-
tes. Although not all individuals with insulin resist-
ance will go on to develop type 2 diabetes, in those
that do, overt type 2 diabetes develops when b-cells
are no longer able to compensate for insulin
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SUMMARY
Type 2 diabetes is characterised by a gradual decline in glycaemic control and pro-
gression from oral glucose-lowering monotherapy to combination therapy and exo-
genous insulin therapy. Functional decline of the insulin-secreting b-cells is largely
responsible for the deterioration in glycaemic control. Preservation of b-cell func-
tionality, in addition to maintaining glycaemic control and reducing insulin resist-
ance, is now regarded as a key target for long-term management strategies. Early,
aggressive intervention with combination therapy is emerging as a valid approach
to optimise long-term outcomes and combining agents with differing modes of
action and secondary effect proﬁles should prove valuable. Sulfonylureas and thia-
zolidinediones exert their glucose-lowering effect through differing mechanisms of
action – the sulfonylureas by stimulating insulin secretion, whereas the thiazolidin-
ediones are insulin sensitisers. Both agents offer excellent improvements in
glycaemic control when given as monotherapy or in combination. The thiazolidin-
ediones protect b-cell structural and functional integrity and functionality and com-
plement the sulfonylureas by inducing and maintaining improvements in insulin
resistance, the abnormal lipid proﬁle associated with type 2 diabetes and other
cardiovascular risk factors. Thus, there is a strong rationale to support the addition
of thiazolidinediones to sulfonylureas as a treatment option for type 2 diabetes.
This combination may be particularly effective in the early stages of the disease
when b-cell function is at its highest, allowing maximal beneﬁt to be obtained
from the insulin secretion-promoting abilities of the sulfonylureas and the b-cell-
protective effects of the thiazolidinediones.
Message for the Clinic
• The combination of a sulfonylurea and a
thiazolidinedione may be a particularly effective
treatment option in the early stages of type 2
diabetes when b-cell function is at its highest.
This allows maximal beneﬁt to be obtained from
the insulin secretion-promoting abilities of the
sulfonylureas and the b-cell-protective effects of
the thiazolidinediones.
Review Criteria
• Evidence was identiﬁed through a search of
MEDLINE and EMBASE from January 1996 to
October 2006, using the search terms
‘thiazolidinedione’, ‘pioglitazone’, ‘rosiglitazone’,
‘sulfonylurea’, and ‘mechanism of action’,
‘pleiotropic’, ‘insulin resistance’ and ‘type 2
diabetes’.
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to the decline in b-cell function by inducing endo-
plasmic reticulum stress as a consequence of an
increased demand for insulin (11). This is in addi-
tion to the toxic effects of elevated glucose and lipid
levels because of their impaired metabolic processing
in the presence of insulin resistance (12).
Today, a variety of agents of differing modes of
action are available to improve glycaemic control. The
sulfonylureas (e.g. glipizide, glyburide, glimepiride
and gliclazide) are insulin secretagogues that act to
increase insulin secretion. Biguanides (principally
metformin), reduce hepatic glucose output and
increase the uptake of glucose by peripheral tissues.
More recently, the thiazolidinediones (pioglitazone
and rosiglitazone) have emerged as novel, effective
glucose-lowering agents (13). The thiazolidinediones
are peroxisome proliferator-activated receptor gamma
(PPARc)-stimulating insulin sensitisers that also act
without increasing insulin secretion. Other, less widely
used agents include the a-glucosidase inhibitor,
acarbose, the incretin mimetic, exenatide, and the new
short-acting insulin secretagogues, repaglinide and
nateglinide. A variety of agents with novel
mechanisms of action are currently in development
and their role in future management regimens has yet
to be deﬁned. All these agents have varying, primary
or secondary, effects on b-cell function. Recent
research effort has focused on deﬁning the effect of
oral glucose-lowering agents in this respect to guide
decisions on appropriate combination therapies to
achieve long-term outcomes beyond glycaemic
control.
This review examines the mechanistic distinctions
in terms of glycaemic control and b-cell functional
preservation and the latest clinical data that support
the rationale for thiazolidinedione–sulfonylurea com-
bination therapy in patients with type 2 diabetes.
Glycaemic control
The sulfonylureas and biguanides formed the main-
stay of oral glucose-lowering therapy from their
introduction in the early 1940s until the 1990s when
thiazolidinediones became available. Sulfonylureas
stimulate endogenous insulin secretion via their
action at the KATP channel in the plasma membrane
of pancreatic b-cells (14) and effectively decrease
HbA1c levels by between 0.8% and 2.0% (15). As sul-
fonylureas act by enhancing insulin secretion, they
are most effective in the early stages of type 2 diabe-
tes when b-cell function is at its greatest. Despite
their initial efﬁcacy, glycaemic control is inevitably
lost over time with the sulfonylureas, necessitating
the introduction of combination therapy to regain
control and prolong the time before progression to
exogenous insulin therapy. In the United Kingdom
Prospective Diabetes Study (UKPDS), 53% of newly
diagnosed type 2 diabetics initially treated with sulfo-
nylureas subsequently required additional treatment
within 6 years to maintain glycaemic control (16). In
the recently published ADOPT study, the proportion
of the patients with type 2 diabetes exceeded the
target fasting blood glucose level of 180 mg/dl after
follow-up (17). Given the direct effects of the sulfo-
nylureas on the b-cell and the potential for b-cell
exhaustion, combination regimens with agents that
improve glycaemia by different modes of action, such
as the thiazolidinediones, are recommended. This
combination may be particularly effective given the
known positive effects of the thiazolidinediones on
b-cell function discussed below.
The thiazolidinediones act as insulin-sensitising
agents and increase the peripheral action of insulin.
They act as ligands of PPARc, which is involved with
the regulation of genes that control glucose homeos-
tasis and lipid metabolism and is found in high con-
centrations in adipose tissue, hepatocytes and skeletal
muscle. These agents have also proved effective in
reducing HbA1c levels and maintaining glycaemic
control, with average reductions in HbA1c levels of
between 0.5% and 1.5% (15,18). Recent evidence
suggests that the thiazolidinediones may be more
effective than sulfonylureas in maintaining glycaemic
control over the long term (17,19). In a direct com-
parison of pioglitazone vs. gliclazide as monotherapy,
signiﬁcantly more pioglitazone-treated patients main-
tained their glycaemic control at 2 years than did
patients treated with gliclazide (19).
Short- and long-term studies with thiazolidinedi-
ones and sulfonylurea in combination have shown
that this combination offers sustained glycaemic con-
trol (20–27). Aljabri et al. (20) found that, compared
with the addition of bedtime insulin to maximal
doses of sulfonylurea or metformin, the addition of
pioglitazone resulted in comparable improvements in
glycaemic control and less hypoglycaemia after
16 weeks of treatment. Although this study did not
report separate results for the sulfonylurea and met-
formin groups, there was an overall reduction in
HbA1c of 1.9% compared with 2.3% for insulin (20).
In another short-term study, Kipnes et al. (27)
looked at the pioglitazone–sulfonylurea combination
exclusively and reported decreases of 0.9% and 1.3%
for pioglitazone doses of 15 and 30 mg, respectively,
over 16 weeks.
Long-term studies also support the sustained bene-
ﬁcial effects of this combination on glycaemic con-
trol (Table 1). In a 6-month study, Comaschi et al.
(23) reported signiﬁcant and sustained reductions in
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fonylurea or metformin. Four further studies of
increasing duration have also conﬁrmed the main-
tenance of glycaemic control following the addition
of pioglitazone to sulfonylurea therapy. In the Quar-
tet study, the addition of pioglitazone to existing sul-
fonylurea therapy resulted in a 1.2% reduction in
HbA1c after 1 year in 319 patients with inadequately
controlled type 2 diabetes (25). Derosa et al. (28)
also reported signiﬁcant (1.3%; p < 0.01 from base-
line) and sustained reductions in HbA1c levels when
either rosiglitazone or pioglitazone were added to
failing glimepiride in 91 patients with type 2 diabetes
and the metabolic syndrome after 1 year. In the
2-year end point of the Quartet study described
above, comparing the addition of pioglitazone or
metformin to failing sulfonylurea therapy, found that
after a rapid decrease in HbA1c levels over the ﬁrst
20 weeks of the study plateaued with overall reduc-
tions of 1.03% and 1.16% for the pioglitazone plus
sulfonylurea and metformin plus sulfonylurea add-
on groups, respectively, after 104 weeks of treatment
(21). The recently presented glycaemic results of the
PROspective pioglitAzone Clinical Trial In macro-
Vascular Events (PROactive) study (22) of 5238
patients with type 2 diabetes and evidence of macro-
vascular disease further support the maintenance of
glycaemic control following the addition of pioglita-
zone to existing sulfonylurea therapy. A subgroup
analysis of the PROactive study looked at the 1001
patients who were managed with sulfonylurea ther-
apy at baseline. Patients treated with pioglitazone
experienced signiﬁcant decreases from baseline in
HbA1c levels that were sustained up to the 34.5-
month assessment and fewer patients switched to or
required addition of metformin or insulin compared
with those who received placebo [Figure 1; (22)].
Effects of thiazolidinediones and
sulfonylureas on b-cell stress
Thiazolidinediones and sulfonylureas exert opposing
effects on b-cell functionality over time. b-cell stress
is reduced with thiazolidinedione therapy, but
enhanced with sulfonylurea therapy (29).
Studies have shown that chronic exposure to
glibenclamide can lead to an acceleration of b-cell
apoptosis and b-cell exhaustion or desensitisation
(30–34). The precise mechanism by which glibencla-
mide initiates b-cell apoptosis remains unclear, but
may involve closure of the inwardly rectifying K
+
sulfonylurea receptor subtype of the ATP-sensitive
Table 1 Long-term glycaemic and lipidaemic effects of combined sulfonylurea and thiazolidinedione therapy in patients with type 2 diabetes
Study Comparator groups N Duration Glycaemic effects Lipidaemic effects
Comaschi et al., 2006 (23) Pioglitazone + sulfonylurea 6 months Signiﬁcant and comparable improvements
in HbA1c at 12 months (p ¼ 0.0001)
Signiﬁcant improvement across all
lipid parameters Pioglitazone + metformin
Torre et al., 2006 (79) Pioglitazone + sulfonylurea 77 6 months Not reported Signiﬁcant decrease in triglyceride
levels in the pioglitazone +
sulfonylurea group only
Signiﬁcant improvement in
HDL-cholesterol levels
Pioglitazone + metformin 103
Derosa et al., 2004 (85) Glimepiride + pioglitazone 45 1 year Signiﬁcant and comparable improvements
in HbA1c at 12 months (p < 0.01)
Signiﬁcant improvement across all
lipid parameters
Glimepiride + rosiglitazone 44 Worsening of multiple lipid parameters
Ginis et al., 2006 (24) Pioglitazone + sulfonylurea 791 1 year Signiﬁcant improvement in both groups
from baseline
Pioglitazone + sulfonylurea: 6.65%
Pioglitazone + metformin: 6.61%
Triglycerides decreased signiﬁcantly
in both groups (p < 0.0001)
Overall reduction of 12.8% for both
groups combined for total cholesterol
Signiﬁcant improvement in HDL- and
LDL-cholesterol levels in both groups
Pioglitazone + metformin 705
PROactive
Charbonnel and Scheen,
2006 (22); Spanheimer
et al., 2006 (78)
Pioglitazone + sulfonylurea 508 3 years Signiﬁcantly greater improvements over
time in HbA1c vs. placebo (p < 0.001
at ﬁnal visit)
Signiﬁcant improvement in triglyceride
and HDL-cholesterol levels vs. placebo Placebo + sulfonylurea 493
Quartet
Charbonnel et al., 2005 (21)
Pioglitazone + sulfonylurea 319 2 years HbA1c reduced by 1.03% Signiﬁcant reduction in triglycerides
and greater increase in
HDL-cholesterol (p £ 0.001) vs.
metformin + sulfonylurea
Metformin + sulfonylurea 320 HbA1c reduced by 1.16%
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ment of Ca
2+ inﬂux mediated by glibenclamide lead-
ing to elevated and toxic cytosolic Ca
2+ levels (33)
and nitric oxide production (30). In addition, pro-
longed exposure to sulfonylurea renders b-cells less
responsive to subsequent sulfonylurea stimulation.
Davalli et al. (31) found that prolonged in vitro
exposure of human pancreatic islets to various insu-
lin secretagogues, including sulfonylureas, resulted in
a reduced capacity to respond to further secretory
stimulation. Interestingly, certain sulfonylureas may
offer a protective effect from hydrogen peroxide-
induced b-cell damage (35).
Several lines of evidence support the beneﬁcial
effects of thiazolidinediones in terms of improving
insulin secretion, preserving b-cell mass and islet
structure and also protecting b-cells from oxidative
stress (36–42). How the thiazolidinediones exert these
protective effects remains unclear. In the presence of
chronically elevated glucose levels (glucotoxicity),
elevated free fatty acid (FFA) levels (lipotoxicity)
appear to play an important role in b-cell damage dur-
ing the early stages of type 2 diabetes, impairing their
functionality and inducing cell death (43,44). In the
presence of both chronic hyperglycaemia and elevated
FFA levels, b-cells synthesise less insulin and lose the
glucose-stimulated insulin secretion response (45,46).
Thiazolidinediones may protect against the toxic
effects of chronically elevated lipid levels by limiting
the exposure of b-cells to circulating FFAs (47) and by
their effects on triglyceride partitioning in tissues.
They may also protect against b-cell apoptosis and
facilitate b-cell proliferation more directly by prevent-
ing Nuclear Factor (NF)kB activation in b-cells
(37,48). Amyloid deposition has also been associated
with increased b-cell apoptosis (49) and a reduction in
amyloid deposition with thiazolidinediones has been
demonstrated in vivo (50). The protective effects of the
thiazolidinediones in this respect may be exerted via
activation of a phosphatidylinositol 3¢-kinase (PI3K)
Akt cascade, which acts to inhibit the human islet
amyloid polypeptide (h-IAPP) induction of apoptosis
(51). Recently a strong effect of pioglitazone on low-
grade-inﬂammation in patients with cardiovascular
disease (CVD) without diabetes has been described,
which may be another way to protect the b-cells (52).
Insulin resistance
Clinical studies have also provided indirect support
for the preservation of b-cell function with thiazolid-
inedione therapy. Homeostasis model assessment
(HOMA) is a mathematical tool that models the glu-
cose–insulin feedback loop in the homeostatic state.
It permits estimations of insulin sensitivity (%S) and
b-cell function (%B) from pairs of fasting glucose
and insulin (or C-peptide) measurements. A 23-week
study of pioglitazone monotherapy showed that there
was an increase in HOMA-%B (53). In a separate
study in drug-naı ¨ve patients with type 2 diabetes,
Wallace et al. (54) reported an increase in HOMA-
%B during 3 months of pioglitazone therapy com-
pared with a small decrease among patients receiving
placebo. In addition, they reported a signiﬁcant
decrease in the pro-insulin/insulin ratio suggesting
that the b-cells were under less stress. This observa-
tion has also been reported for rosiglitazone (55).
Other studies have also reported improvements in
the insulinogenic index (provides a measure of b-cell
function during an oral glucose tolerance test) and
the disposition index (in which the value is corrected
for underlying insulin resistance) (56–58). These
improvements in b-cell function appear to be main-
tained during long-term studies. For example, in
studies comparing pioglitazone and gliclazide either
as monotherapies (19) or as add-on treatments to
existing therapy (59), both agents were associated
with an initial improvement in the HOMA-%B.
However, only patients treated with pioglitazone
were able to maintain this improvement during
2 years of treatment, while those treated with gliclaz-
ide experienced a continued gradual decline, despite
a greater initial improvement [Figure 2; (19,59)].
Studies support an effect for both thiazolidinedi-
ones and sulfonylureas in improving insulin resist-
ance in the short term in type 2 diabetes using
techniques such as the hyperinsulinaemic/euglycae-
Baseline Final visit
8.5
8.0
7.5
7.0
6.5
6.0
6
HbA1c (%)
12 18 24 30
Figure 1 Maintenance of long-term glycaemic control with
combination sulfonylurea and pioglitazone therapy
[Charbonnel and Scheen, 2006 (22)]. The placebo group is
shown by the solid line and squares. The pioglitazone
group is shown by the dashed line and diamonds.
Copyright ª 2005 American Diabetes Association from
Diabetes, vol. 55, 2006; A478. Reprinted with permission
from the American Diabetes Association
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amount of glucose necessary to compensate for an
increased insulin level without causing hypoglycae-
mia) and HOMA-%S (54,60–64). However, direct
comparisons during long-term treatment suggest that
the thiazolidinediones may be better able to improve
and maintain improvements in insulin sensitivity
(19,65). During 1 year of treatment, pioglitazone
therapy was associated with signiﬁcant reductions in
HOMA-%S (p ¼ 0.002 from baseline), whereas no
signiﬁcant decrease was recorded for gliclazide in
patients with type 2 diabetes (65). Similarly, in a
2-year study, Tan et al. (19) found that pioglitazone
was associated with an improvement in HOMA-%S,
while gliclazide was associated with a worsening in
this measure of insulin resistance. Combining sulfo-
nylurea therapy with thiazolidinediones may ensure
long-term beneﬁts in terms of insulin resistance (66).
In the ADOPT study, comparing rosiglitazone
with glibenclamide and with metformin in early type
2 diabetes, rosiglitazone improved insulin resistance
and b-cell function to a signiﬁcantly greater extent
than both competitors did (17).
Control of dyslipidaemia and other
cardiovascular risk factors
In addition to the toxic effects of elevated FFAs on
b-cells, the abnormal lipid proﬁle – including elevated
small dense LDL, lowered HDL-cholesterol and
elevated triglycerides – associated with type 2 diabetes
poses a further burden in terms of increasing the risk
of CVD. Thus, most studies of glucose-lowering ther-
apy now also include an assessment of lipid effects.
Older sulfonylureas appear to be associated with
adverse cardiovascular risks, possibly due to their
binding to ATP-sensitive potassium channels in
cardiomyocytes and vascular smooth muscle cells
(67,68). However, how these effects might translate
into clinical implications is poorly deﬁned and the
newer sulfonylureas appear to be associated with a
lower risk of adverse cardiovascular events, such as
myocardial infarction and may in fact inhibit athero-
matous plaque formation (69,70). Patients with pre-
existing CVD may be particularly sensitive to the
effects of sulfonylureas in this respect (71,72), as
studies in which such patients were excluded showed
no increased risk of cardiovascular mortality (73).
No primary effects on lipid proﬁle induced by sulfo-
nylureas are seen.
Pioglitazone has been shown to improve the lipid
proﬁle in patients with type 2 diabetes by increasing
HDL-cholesterol levels, decreasing triglyceride levels
and increasing the lipoprotein particle size of LDL in
combination regimens with sulfonylurea (20,27,74).
Evidence is emerging of a differential effect between
the thiazolidinediones in this respect (75,76). In the
study reported by Peters Harmel et al. (76) described
above, the addition of pioglitazone to metformin
and/or sulfonylurea therapy was associated with a
decrease in triglyceride levels and an increase in
HDL-cholesterol levels. The addition of rosiglitazone
also resulted in an increase in HDL-cholesterol, but
with no signiﬁcant improvement in triglyceride levels
and an overall increase in total cholesterol levels
(76). More recently, Khan et al. (75) reported on the
improvement in lipid parameters in patients switched
from rosiglitazone–sulfonylurea combination therapy
to pioglitazone–sulfonylurea therapy in addition to
continued stable statin therapy. After 17 weeks of
treatment, replacement of rosiglitazone with pioglita-
zone was associated with signiﬁcant improvements
in triglyceride and total cholesterol levels and more
modest improvements in LDL-cholesterol (75).
Long-term studies have shown that the beneﬁcial
effects associated with pioglitazone therapy are
maintained over months and years [Table 1;
(21,24,74,77–79)].
Thiazolidinediones have other advantages over tra-
ditionally employed oral agents, including additional
Weeks of treatment
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* * * * * *
‡
‡
‡
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Figure 2 Improvement in b-cell function over 2 years of treatment with either pioglitazone or gliclazide [Tan et al. 2005
(19)]. The gliclazide group is shown by the solid line and squares. The pioglitazone group is shown by the dashed line and
diamonds; *p < 0.0001, ‡p < 0.01, †p < 0.05. Copyright ª 2005 American Diabetes Association. From Diabetes Care, vol.
28, 2005, 544–550. Reprinted with permission from the American Diabetes Association
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the pro-thrombotic state and blood pressure. When
given in combination with the sulfonylurea,
glimepiride, both rosiglitazone and pioglitazone have
been shown to improve key components of the pro-
thrombotic state associated with type 2 diabetes
[including plasminogen activator inhibitor 1 levels]
(28). In a study of patients with type 2 diabetes and
the metabolic syndrome failing on initial therapy
with a sulfonylurea or metformin, combination
therapy with glimepiride and either pioglitazone or
rosiglitazone was associated with signiﬁcant improve-
ments in both systolic and diastolic blood pressure
over 12 months (80). In addition, thiazolidinediones
have been shown to lower the levels of a number of
inﬂammatory parameters, including high sensitivity
C-reactive protein and matrix metalloproteinase
(52,81–84).
In a recently published study comparing the efﬁc-
acy of simvastatin, pioglitazone and the combination
of both in patients with CVD, but without diabetes,
the combination of pioglitazone and statin had
additive and complimentary effects on a broad spec-
trum of inﬂammatory parameters and the lipopro-
tein proﬁle independent of HbA1c level (52).
Conclusions
Type 2 diabetes manifests in an insulin-resistant
individual when pancreatic b-cells are unable to pro-
duce sufﬁcient insulin to overcome insulin resistance
in the muscles and liver. Intervening early to attain
glycaemic control and protect b-cell function is now
regarded as central to improving long-term outcomes
for patients with type 2 diabetes. The insulin secreta-
gogue sulfonylureas and biguanides represented the
mainstay of oral glucose-lowering therapy from their
development in the 1940s to the 1990s. Today, these
agents are still used and are proving especially useful
in early combination therapy regimens with agents
that improve glycaemic control by different molecu-
lar mechanisms. In patients treated with a sulfonyl-
urea, there is a strong rationale to support the early
combination with thiazolidinediones in type 2 diabe-
tes. In addition to improving and maintaining glyc-
aemic control, the thiazolidinediones reduce b-cell
stress, improve insulin resistance and modify a vari-
ety of cardiovascular risk factors, including the
abnormal lipid proﬁle and increased low-grade
inﬂammation activity associated with type 2 diabetes.
The combined beneﬁts of thiazolidinediones and sul-
fonylureas may delay the progression of type 2 diabe-
tes and the need for exogenous insulin therapy, and
may also offer beneﬁts in terms of reduced risk of
CVD.
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